|
Ilan is a Partner of Prospect Venture Partners. Prior to joining Prospect Venture Partners III, Ilan was a Principal at MPM Capital, and had been promoted to General Partner for MPM's next fund. At MPM, Ilan was involved with investments in biotechnology and specialty pharmaceutical companies including Neuromed Pharmaceuticals, Pharmasset, KaloBios, Rinat Neuroscience, ARYx Therapeutics, in addition to Somaxon Pharmaceuticals (NASDAQ:SOMX) where he serves on the Board of Directors. Ilan also worked with MPM Capital's BioEquities hedge fund, which invests in small- to mid-cap public biotechnology companies. Prior to joining MPM Capital in 2000, Ilan was the Science Editor of BioCentury Publications Inc., a biotechnology news and analysis publication. Ilan received a Ph.D. in cell biology and biochemistry from the University of California at San Francisco (UCSF), and a B.A. in Molecular and Cell Biology from U.C. Berkeley. | 